You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • TP021/#1540  Reframe-O1/ENGOT-OV79/GOG-3086: a phase 2/3 open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice chemotherapy in relapsed platinum-resistant EOC expressing folate receptor-alpha

Citation Tools

Article menu

Download PDFPDF

ePoster Viewing: Trials-in-Progress
AS11. Ovarian cancer
TP021/#1540  Reframe-O1/ENGOT-OV79/GOG-3086: a phase 2/3 open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice chemotherapy in relapsed platinum-resistant EOC expressing folate receptor-alpha
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Wendel Naumann R, González-Martín A, Herzog T, et al
TP021/#1540  Reframe-O1/ENGOT-OV79/GOG-3086: a phase 2/3 open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice chemotherapy in relapsed platinum-resistant EOC expressing folate receptor-alpha
International Journal of Gynecologic Cancer 2023;33:A255.